{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:31:55Z","timestamp":1789835515432,"version":"4.0.1"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.coph.2025.102583","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:16:00Z","timestamp":1763702160000},"page":"102583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Beyond tumor necrosis factor and interleukin-12\/23: The rise of interleukin-23 inhibitors in inflammatory bowel disease management"],"prefix":"10.1016","volume":"86","author":[{"given":"Catarina","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurulamin M.","family":"Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-0139","authenticated-orcid":false,"given":"Maria Manuela","family":"Estevinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.coph.2025.102583_bib1","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjae082","article-title":"Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies","volume":"18","author":"Caron","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2025.102583_bib2","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/gut.2011.238477","article-title":"Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease","volume":"60","author":"Kim","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.coph.2025.102583_bib3","article-title":"Efficacy and safety of IL-23 p19 inhibitors in the treatment for inflammatory bowel disease: a systematic review and meta-analysis","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2025.102583_bib4","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40265-023-01882-9","article-title":"Targeting IL-23 for IBD: rationale and progress to date","volume":"83","author":"Vuyyuru","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2025.102583_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/biology14040347","article-title":"The role of IL-23 in the development of inflammatory diseases","volume":"14","author":"Garc\u00eda-Dom\u00ednguez","year":"2025","journal-title":"Biology"},{"key":"10.1016\/j.coph.2025.102583_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.coph.2025.102583_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3390\/ijms26010121","article-title":"Key interleukins in inflammatory bowel disease\u2014A review of recent studies","volume":"26","author":"Aebisher","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coph.2025.102583_bib8","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/biom14121489","article-title":"Interleukin-27 and autoimmune disorders: a compressive review of immunological functions","volume":"14","author":"Yazdanpanah","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.coph.2025.102583_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41420-023-01366-5","article-title":"Interleukin-35 -producing B cells rescues inflammatory bowel disease in a mouse model via STAT3 phosphorylation and intestinal microbiota modification","volume":"9","author":"Xie","year":"2023","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.coph.2025.102583_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12026-023-09432-x","article-title":"Increased synthesis and intestinal expression of IL-39 in patients with inflammatory bowel disease","volume":"72","author":"Fonseca-Camarillo","year":"2024","journal-title":"Immunol Res"},{"key":"10.1016\/j.coph.2025.102583_bib11","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20061099","article-title":"Interleukin-23 drives innate and T cell-mediated intestinal inflammation","volume":"203","author":"Hue","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2025.102583_bib12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.immuni.2006.05.017","article-title":"Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology","volume":"25","author":"Uhlig","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2025.102583_bib13","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coph.2025.102583_bib14","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1189\/jlb.0810456","article-title":"The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity","volume":"89","author":"Liu","year":"2011","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.coph.2025.102583_bib15","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1136\/gutjnl-2014-309014","article-title":"Tissue-infiltrating neutrophils represent the main source of IL-23 in the colon of patients with IBD","volume":"65","author":"Kvedaraite","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.coph.2025.102583_bib16","first-page":"116","article-title":"Evaluation of interleukin 23 (IL-23) as a non-invasive test of disease severity in patients with ulcerative colitis","volume":"19","author":"Youssef","year":"2018","journal-title":"Arab J Gastroenterol Off Publ Pan-Arab Assoc Gastroenterol"},{"key":"10.1016\/j.coph.2025.102583_bib17","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease","volume":"68","author":"Schmitt","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.coph.2025.102583_bib18","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2025.102583_bib19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","article-title":"Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study","volume":"3","author":"Feagan","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2025.102583_bib20","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.coph.2025.102583_bib21","article-title":"Extended risankizumab treatment in patients with crohn's disease who did not achieve clinical response to induction treatment","author":"Panaccione","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2025.102583_bib22","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"28","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2025.102583_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.gastha.2024.100603","article-title":"Effect of Risankizumab induction and maintenance therapy on the rate of hospitalization in patients with crohn's disease","volume":"4","author":"Feagan","year":"2025","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.coph.2025.102583_bib24","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ecco-jcc\/jjad206","article-title":"Risankizumab induction therapy achieves early symptom improvements that are associated with future clinical and endoscopic outcomes in crohn's disease: post hoc analysis of the ADVANCE, MOTIVATE, and FORTIFY phase 3 studies","volume":"18","author":"Colombel","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2025.102583_bib25","first-page":"662","article-title":"Outcomes after dose intensification of Risankizumab for crohn's disease","volume":"23","author":"Dalal","year":"2025","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"10.1016\/j.coph.2025.102583_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izaf130","article-title":"Efficacy of Risankizumab dose escalation among patients with inflammatory bowel disease","author":"Schreiber-Stainthorp","year":"2025","journal-title":"Inflamm Bowel Dis"},{"issue":"Supplement_1","key":"10.1016\/j.coph.2025.102583_bib27","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1093\/ibd\/izae020.192","article-title":"Risankizumab dose escalation in patients with CROHN\u2019S disease","volume":"30","author":"Nichols","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coph.2025.102583_sref28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe crohn's disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102583_bib29","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with crohn's disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2025.102583_bib30","first-page":"1878","article-title":"Effects of mirikizumab on histologic resolution of crohn's disease in a randomized controlled phase 2 trial","volume":"22","author":"Magro","year":"2024","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.coph.2025.102583_sref31","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.coph.2025.102583_bib32","doi-asserted-by":"crossref","first-page":"P358","DOI":"10.1016\/S0140-6736(25)00681-6","volume":"406","author":"Remo","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2025.102583_bib33","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of crohn's disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2025.102583_sref34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2025.102583_bib35","unstructured":"Efficacy and safety of Guselkumab therapy in patients with moderately to severely active Crohn's disease: results of the Galaxi 2 & 3 phase 3 studies [Internet]. ACR Meeting Abstracts. [cited 2025 July 7]. Available from: https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-guselkumab-therapy-in-patients-with-moderately-to-severely-active-crohns-disease-results-of-the-galaxi-2-3-phase-3-studies\/."},{"key":"10.1016\/j.coph.2025.102583_bib36","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/j.gastro.2025.02.033","article-title":"Efficacy and safety of Guselkumab subcutaneous induction and maintenance in participants with moderately to severely active crohn's disease: results from the phase 3 GRAVITI study","volume":"169","author":"Hart","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2025.102583_bib37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(25)00681-6","volume":"406","author":"Panaccione","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2025.102583_bib38","series-title":"A study of combination therapy with Guselkumab and golimumab in participants with moderately to severely active crohn's disease (DUET-CD)","year":"2025"},{"key":"10.1016\/j.coph.2025.102583_bib39","series-title":"Transmural healing and disease-modifying effect of Guselkumab in crohn's disease patients (REASON)","year":"2025"},{"key":"10.1016\/j.coph.2025.102583_bib40","series-title":"A study of Guselkumab in participants with fistulizing, perianal crohn's disease (FUZION CD)","year":"2025"},{"key":"10.1016\/j.coph.2025.102583_bib41","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2025.102583_bib42","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102583_sref43","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/ibd\/izae024","article-title":"Two-year efficacy and safety of mirikizumab following 104 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study","volume":"30","author":"Sands","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coph.2025.102583_bib44","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/ibd\/izae253","article-title":"Three-year efficacy and safety of mirikizumab following 152 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study","volume":"31","author":"Sands","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coph.2025.102583_bib45","unstructured":"Additional risankizumab therapy is effective in patients with moderately to severely active ulcerative colitis who did not achieve clinical response to initial 12-week induction therapy: an analysis of phase 3 INSPIRE and COMMAND studies [Internet]. [cited 2025 Sept 23]. Available from: https:\/\/ddw.digitellinc.com\/p\/s\/additional-risankizumab-therapy-is-effective-in-patients-with-moderately-to-severely-active-ulcerative-colitis-who-did-not-achieve-clinical-response-to-initial-12-week-induction-therapy-an-analysis-of-6654."},{"key":"10.1016\/j.coph.2025.102583_sref46","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.coph.2025.102583_bib47","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study","volume":"165","author":"Peyrin-Biroulet","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2025.102583_bib48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2025.102583_sref49","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Supplement_1","key":"10.1016\/j.coph.2025.102583_bib50","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/ecco-jcc\/jjae190.0010","article-title":"OP10 efficacy and safety of subcutaneous guselkumab induction therapy in patients with ulcerative colitis: results through week 12 from the phase 3 ASTRO study","volume":"19","author":"Peyrin-Biroulet","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2025.102583_bib51","series-title":"A study of combination therapy with Guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (DUET-UC)","year":"2025"},{"key":"10.1016\/j.coph.2025.102583_bib52","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/jcm14031001","article-title":"Role of Mirikizumab in the treatment of inflammatory bowel disease\u2014from bench to bedside","volume":"14","author":"Colwill","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.coph.2025.102583_bib53","series-title":"Summary of risk management plan (RMP) for Mirikizumab [Internet]","year":"2025"},{"key":"10.1016\/j.coph.2025.102583_bib54","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/14712598.2024.2412650","article-title":"An evaluation of mirikizumab for the treatment of ulcerative colitis","volume":"24","author":"White","year":"2024","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.coph.2025.102583_bib55","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s13555-024-01238-5","article-title":"Long-term safety of risankizumab in patients with psoriatic disease: a comprehensive analysis from clinical trials","volume":"14","author":"Gordon","year":"2024","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.coph.2025.102583_bib56","doi-asserted-by":"crossref","DOI":"10.1097\/CLD.0000000000000199","article-title":"Hepatotoxicity in inflammatory bowel disease: immunomodulators, biologics, and beyond","volume":"23","author":"Bj\u00f6rnsson","year":"2024","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.coph.2025.102583_bib57","doi-asserted-by":"crossref","DOI":"10.1177\/17562848251338743","article-title":"Clinical insights into IL-23 inhibition: risankizumab for Crohn's disease through a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Huang","year":"2025","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.coph.2025.102583_bib58","doi-asserted-by":"crossref","DOI":"10.1177\/17562848251338743","article-title":"Clinical insights into IL-23 inhibition: risankizumab for Crohn's disease through a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Huang","year":"2025","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.coph.2025.102583_bib59","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.cgh.2024.09.027","article-title":"Long-term effectiveness and safety of risankizumab in patients with crohn's disease","volume":"23","author":"Zinger","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2025.102583_bib60","doi-asserted-by":"crossref","unstructured":"P0608 safety of guselkumab in inflammatory bowel disease up to 1 year: integrated safety analysis of phase 2 and 3 studies in Crohn's disease and ulcerative colitis | J Crohn Colitis Oxf Acad [Internet]. [cited 2025 Sept 23]. Available from: https:\/\/academic.oup.com\/ecco-jcc\/article\/19\/Supplement_1\/i1205\/7967516.","DOI":"10.1093\/ecco-jcc\/jjae190.0782"},{"key":"10.1016\/j.coph.2025.102583_bib61","series-title":"BLA approval for OMVOH (Mirikizumab-mrkz) - indication: ulcerative colitis [Internet]. Silver Spring (MD)","year":"2023"},{"key":"10.1016\/j.coph.2025.102583_bib62","series-title":"BLA approval for Skyrizi (Risankizumab-rzaa) - indication: ulcerative colitis [Internet]. Silver Spring (MD)","year":"2024"},{"key":"10.1016\/j.coph.2025.102583_bib63","series-title":"BLA approval for Tremfya (guselkumab) \u2013 indication: ulcerative colitis [Internet]. Silver Spring (MD)","year":"2024"},{"key":"10.1016\/j.coph.2025.102583_bib64","unstructured":"European Medicines Agency. Skyrizi - EPAR product information [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/skyrizi?utm_source=chatgpt.com."},{"key":"10.1016\/j.coph.2025.102583_bib65","unstructured":"European Medicines Agency. Omvoh : EPAR - Product information [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omvoh-epar-product-information_en.pdf."},{"key":"10.1016\/j.coph.2025.102583_bib66","unstructured":"European Medicines Agency. CHMP post-authorisation summary of positive opinion for Omvoh (X-06-G) [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/variation\/omvoh."},{"issue":"Supplement_1","key":"10.1016\/j.coph.2025.102583_bib67","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae190.0891","article-title":"P0717 real-world data of Mirikizumab in the induction and maintenance therapy for ulcerative colitis","volume":"19","author":"Eleftheriadou","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2025.102583_bib68","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1007\/s10620-025-08950-y","article-title":"Mirikizumab in the treatment of ulcerative colitis: initial real-world data in a population from a large tertiary center","volume":"70","author":"St-Pierre","year":"2025","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.coph.2025.102583_bib69","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1111\/apt.70140","article-title":"Real-world effectiveness and safety of mirikizumab induction therapy in patients with ulcerative colitis: a multicentre retrospective observational study","volume":"61","author":"Takagi","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2025.102583_bib70","series-title":"BLA approval for skyrizi (Risankizumab-rzaa) - indication: crohn's disease [Internet]","year":"2022"},{"key":"10.1016\/j.coph.2025.102583_bib71","series-title":"BLA approval for OMVOH (Mirikizumab-mrkz) - indication: crohn's disease [Internet]","year":"2025"},{"key":"10.1016\/j.coph.2025.102583_bib72","series-title":"BLA approval for tremfya (guselkumab) \u2013 indication: crohn's disease [Internet]","year":"2025"},{"key":"10.1016\/j.coph.2025.102583_bib73","series-title":"Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis","author":"Barberio","year":"2023"},{"key":"10.1016\/j.coph.2025.102583_bib74","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf070","article-title":"A multicenter study of the real-world effectiveness and safety of risankizumab in Crohn's disease","volume":"19","author":"Johnson","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"Supplement_1","key":"10.1016\/j.coph.2025.102583_bib75","doi-asserted-by":"crossref","first-page":"i1586","DOI":"10.1093\/ecco-jcc\/jjae190.1006","article-title":"P0832 real-world effectiveness of risankizumab in Crohn's disease: the UK experience","volume":"19","author":"Elford","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"Supplement_1","key":"10.1016\/j.coph.2025.102583_bib76","doi-asserted-by":"crossref","first-page":"i1208","DOI":"10.1093\/ecco-jcc\/jjae190.0783","article-title":"P0609 real-world short and long-term effectiveness of risankizumab in refractory Crohn's disease: RISANCROHN study from the ENEIDA registry","volume":"19","author":"Barreiro-de Acosta","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2025.102583_bib77","first-page":"2451","article-title":"Long-term outcome of Risankizumab in crohn's disease: a real-world GETAID study","volume":"22","author":"Fumery","year":"2024","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc."},{"key":"10.1016\/j.coph.2025.102583_bib78","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/apt.17358","article-title":"Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: a GETAID multicentre cohort study","volume":"57","author":"Fumery","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2025.102583_bib79","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1093\/ibd\/izaf018","article-title":"Efficacy of Mirikizumab in patients with prior ustekinumab exposure: a case series","volume":"31","author":"Sawada","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coph.2025.102583_bib80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2024.05.036","article-title":"Targeting the interleukin 23 pathway in inflammatory bowel disease","volume":"168","author":"Bourgonje","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2025.102583_bib81","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/ibd\/izae182","article-title":"Low placental transfer rates of risankizumab among pregnant women with inflammatory bowel disease","volume":"13","author":"Mahadevan","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coph.2025.102583_bib82","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cgh.2025.04.005","article-title":"Global consensus statement on the management of pregnancy in inflammatory bowel disease","volume":"23","author":"Mahadevan","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2025.102583_bib83","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/ced.14979","article-title":"Anti-interleukin-23 for psoriasis in elderly patients: Guselkumab, risankizumab and tildrakizumab in real-world practice","volume":"47","author":"Ruggiero","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"Supplement_1","key":"10.1016\/j.coph.2025.102583_bib84","doi-asserted-by":"crossref","first-page":"i2001","DOI":"10.1093\/ecco-jcc\/jjae190.1263","article-title":"P1089 efficacy and safety of mirikizumab as induction and maintenance treatment in adults 60 years or older with moderately to severely active ulcerative colitis","volume":"19","author":"Sturm","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.coph.2025.102583_bib85","unstructured":"Colombel JF, Danese S, Martin N, Kligys K, Zambrano J, Duan WR, et al. Safety profile of risankizumab in crohn\u2019s disease patients by age: post-hoc analysis of the phase 3 advance, motivate, and fortify studies [Internet]. Digest Dis Week. [cited 2025 Sept 25]. Available from: https:\/\/eposters.ddw.org\/ddw\/2023\/ddw-2023\/380622\/jean.frederic.colombel.safety.profile.of.risankizumab.in.crohns.disease.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D2%2Aspeaker%3D904104."},{"key":"10.1016\/j.coph.2025.102583_bib86","unstructured":"European Medicines Agency. Omvoh : EPAR - Product information [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/omvoh-epar-product-information_en.pdf."},{"key":"10.1016\/j.coph.2025.102583_bib87","unstructured":"European Medicines Agency. Tremfya : EPAR - Product information [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tremfya-epar-product-information_en.pdf."},{"key":"10.1016\/j.coph.2025.102583_bib88","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1038\/s41467-022-33331-8","article-title":"Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy","volume":"13","author":"Pavlidis","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2025.102583_bib89","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1053\/j.gastro.2018.06.034","article-title":"Diet modifies colonic microbiota and CD4+ T-Cell repertoire to induce flares of colitis in mice with myeloid-cell expression of interleukin 23","volume":"155","author":"Chen","year":"2018","journal-title":"Gastroenterology"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:02:29Z","timestamp":1773334949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489225000797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":89,"alternative-id":["S1471489225000797"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2025.102583","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond tumor necrosis factor and interleukin-12\/23: The rise of interleukin-23 inhibitors in inflammatory bowel disease management","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2025.102583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102583"}}